What 560 million patients deserve to know

Modern medicine has spent decades, trying to cure osteoarthritis.

But they failed.

Every drug on the market today does the same thing: it masks the pain. Meanwhile, the cartilage in your joints continues to deteriorate. The disease keeps progressing. And the drugs just make sure you don't feel it happening.

500 million people worldwide suffer from this disease. And in plain English, the entire $560 billion osteoarthritis industry is built on a lie — that managing symptoms is the same as treating the disease. It isn't.

That's why I find Cytonics so fascinating.

This small medical startup did something that none of the pharmaceutical giants bothered to do. They asked a simple question: 

What if the human body already produces a protein that protects joint cartilage… and what if we could make it more powerful?

And that's exactly what they found. Their researchers identified a naturally occurring protein that shields joints from degradation. Then they genetically engineered a version that is 200% more potent than what your body produces on its own.

This is not another painkiller. This is a next-gen therapy designed to treat the root cause of the disease.

The early results are remarkable. Phase 1 human safety trials recently concluded with zero reported adverse events. And more than 10,000 patients have already been treated with the company's first-generation therapy.

Now, you might be wondering how confident insiders are in this technology. 

So consider this: Rener Gracie — one of the most respected names in martial arts, a third-generation Brazilian Jiu-Jitsu master whose family literally invented the sport — recently made a seven-figure personal investment. So did his wife Eve, a former WWE champion. These are elite athletes who have spent their entire lives depending on their joints. And now they put their own money behind this company.

Here's why that matters to you…

Opportunities like this — early-stage medical breakthroughs with real clinical data — are almost never available to individual investors. The venture capital firms and institutional funds get there first. By the time you hear about it, the easy money has already been made.

But Cytonics management made an unusual decision. They opened a Regulation CF offering, which allows everyday investors to participate alongside the 7,000 backers who have already taken a position.

I'd encourage you to look at this deal carefully. The science is compelling. The clinical data is clean. And the market — a $560 billion problem with no real solution — is enormous.

Click here to review the deal before it closes.

Disclaimer: This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://invest.cytonics.com. Forward-looking statements are subject to risks and uncertainties. There is no guarantee of performance. Past performance does not predict future results. All investments involve risk, including loss of principal.